journal
MENU ▼
Read by QxMD icon Read
search

Cancer Management and Research

journal
https://www.readbyqxmd.com/read/27877066/implantation-of-permanent-pleural-catheter-for-palliation-of-malignant-pleural-effusion
#1
Michelle Meier, Marie Riis Mortensen, Lene Unmack Larsen
PURPOSE: Malignant pleural effusion (MPE) is a disabling condition caused in most instances by far-advanced cancer. The treatment is palliative and should ideally be minimally invasive. The aim of this retrospective study was to evaluate the effectiveness of implantation of a permanent PleurX catheter in the treatment of recurrent MPE in patients with terminal cancer disease. PATIENTS AND METHODS: Eighteen consecutive patients with terminal cancer and MPE, who had a permanent PleurX catheter implanted in the period from February 2014 to August 2015, were retrospectively evaluated...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27799819/treatment-challenges-for-community-oncologists-treating-postmenopausal-women-with-endocrine-resistant-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer
#2
https://www.readbyqxmd.com/read/27695363/atypical-teratoid-rhabdoid-tumors-challenges-and-search-for-solutions
#3
Ahitagni Biswas, Lakhan Kashyap, Aanchal Kakkar, Chitra Sarkar, Pramod Kumar Julka
Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal central nervous system tumor commonly affecting children <3 years of age. It roughly constitutes 1%-2% of all pediatric central nervous system tumors. Recent data show that it is the most common malignant central nervous system tumor in children <6 months of age. Management of this aggressive tumor is associated with a myriad of diagnostic and therapeutic challenges. On the basis of radiology and histopathology alone, distinction of AT/RT from medulloblastoma or primitive neuroectodermal tumor is difficult, and hence this tumor has been commonly misdiagnosed as primitive neuroectodermal tumor for decades...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27578998/role-of-tolvaptan-in-the-management-of-hyponatremia-in-patients-with-lung-and-other-cancers-current-data-and-future-perspectives
#4
REVIEW
Bijin Thajudeen, Abdulla K Salahudeen
Hyponatremia is the most frequently observed electrolyte abnormality in clinical practice, and its frequency is almost double in hospitalized cancer patients. As a subset of cancer, hyponatremia is quite common in lung cancer patients, and it is often coupled with the diagnosis of syndrome of inappropriate antidiuretic hormone secretion. The presence of hyponatremia is consequential in that its presence adversely affects cancer patients' prognosis and outcomes. Limited data suggest that correcting hyponatremia in lung cancer patients can increase response to anticancer treatment, may help reduce length of hospital stay and cost, and reduce morbidity and mortality...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27574465/advanced-soft-tissue-sarcoma-and-treatment-options-critical-appraisal-of-trabectedin
#5
REVIEW
Ingrid M E Desar, Anastasia Constantinidou, Suzanne E J Kaal, Robin L Jones, Winette T A van der Graaf
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesenchymal origin. This paper reviews the current status of systemic treatment in advanced and metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its efficacy in first-line systemic therapy and beyond first-line systemic therapy...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27468248/treatment-challenges-for-community-oncologists-treating-postmenopausal-women-with-endocrine-resistant-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-advanced-breast-cancer
#6
REVIEW
William J Gradishar
Community-based oncologists are faced with challenges and opportunities when delivering quality patient care, including high patient volumes and diminished resources; however, there may be the potential to deliver increased patient education and subsequently improve outcomes. This review discusses the treatment of postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2- negative advanced breast cancer in order to illustrate considerations in the provision of pertinent quality education in the treatment of these patients and the management of therapy-related adverse events...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27390532/erratum-reappraisal-of-the-role-of-dolasetron-in-prevention-and-treatment-of-nausea-and-vomiting-associated-with-surgery-or-chemotherapy-erratum
#7
(no author information available yet)
[This corrects the article on p. 67 in vol. 4, PMID: 22427733.].
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27382332/fosaprepitant-dimeglumine-for-the-management-of-chemotherapy-induced-nausea-and-vomiting-patient-selection-and-perspectives
#8
REVIEW
Nellowe Candelario, Marvin Louis Roy Lu
Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of antineoplastic agents. Several treatment regimens are used to address this problem. Fosaprepitant is a neurokinin-1 receptor blocker used in the prevention and treatment of CINV, especially for moderately and severely emetogenic chemotherapy. It is highly effective in the treatment of delayed CINV. Data from previous studies show that fosaprepitant is noninferior to aprepitant in the management of CINV. Fosaprepitant is given as a single-dose intravenous infusion, thus offering better patient compliance...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27313476/treatment-patterns-health-state-and-health-care-resource-utilization-of-patients-with-radioactive-iodine-refractory-differentiated-thyroid-cancer
#9
Andrew G Gianoukakis, Natalia M Flores, Corey L Pelletier, Anna Forsythe, Gregory R Wolfe, Matthew H Taylor
BACKGROUND: Patients with differentiated thyroid cancer (DTC) often respond well to treatment but some become refractory to radioactive iodine (RAI) treatment, and treatment options are limited. Despite the humanistic and economic burden RAI refractory disease imposes on patients, published research concerning treatment patterns and health care resource utilization is sparse. METHODS: Data were collected from an online retrospective chart review study in the US and five European Union (EU) countries (France, Germany, Italy, Spain, and UK) with physicians recruited from an online panel...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27274311/novel-approaches-to-target-her2-positive-breast-cancer-trastuzumab-emtansine
#10
REVIEW
Gonzalo Recondo, Maximo de la Vega, Fernando Galanternik, Enrique Díaz-Cantón, Bernardo Amadeo Leone, José Pablo Leone
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that results from the combination of trastuzumab and DM1, a derivative of the antimicrotubule agent maytansine. This molecule has the ability to enhance cytotoxic drug delivery to specifically targeted cells that overexpress HER2, therefore, maximizing efficacy while sparing toxicity...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27274310/dronabinol-for-chemotherapy-induced-nausea-and-vomiting-unresponsive-to-antiemetics
#11
REVIEW
Megan Brafford May, Ashley E Glode
Chemotherapy-induced nausea and vomiting (CINV) is one of the most common symptoms feared by patients, but may be prevented or lessened with appropriate medications. Several antiemetic options exist to manage CINV. Corticosteroids, serotonin receptor antagonists, and neurokinin receptor antagonists are the classes most commonly used in the prevention of CINV. There are many alternative drug classes utilized for the prevention and management of CINV such as antihistamines, benzodiazepines, anticonvulsants, cannabinoids, and dopamine receptor antagonists...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27274309/discoveries-and-application-of-prostate-specific-antigen-and-some-proposals-to-optimize-prostate-cancer-screening
#12
Shinkan Tokudome, Ryosuke Ando, Yoshiro Koda
The discoveries and application of prostate-specific antigen (PSA) have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa) patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27217796/multidisciplinary-management-for-esophageal-and-gastric-cancer
#13
REVIEW
Megan M Boniface, Sachin B Wani, Tracey E Schefter, Phillip J Koo, Cheryl Meguid, Stephen Leong, Jeffrey B Kaplan, Lisa J Wingrove, Martin D McCarter
The management of esophageal and gastric cancer is complex and involves multiple specialists in an effort to optimize patient outcomes. Utilizing a multidisciplinary team approach starting from the initial staging evaluation ensures that all members are in agreement with the plan of care. Treatment selection for esophageal and gastric cancer often involves a combination of chemotherapy, radiation, surgery, and palliative interventions (endoscopic and surgical), and direct communication between specialists in these fields is needed to ensure appropriate clinical decision making...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/27069372/proactive-management-strategies-for-potential-gastrointestinal-adverse-reactions-with-ceritinib-in-patients-with-advanced-alk-positive-non-small-cell-lung-cancer
#14
Eric S Schaefer, Christina Baik
Anaplastic lymphoma kinase (ALK) gene fusions occur in 3%-7% of non-small-cell lung cancer (NSCLC) cases. Ceritinib, a once-daily, oral ALK inhibitor, has activity against crizotinib-resistant and crizotinib-naïve NSCLC, including brain metastases. Ceritinib (Zykadia™) was granted accelerated approval by the US Food and Drug Administration in 2014 for treating crizotinib-resistant ALK-positive NSCLC. Adverse events (AEs), particularly gastrointestinal (GI) AEs, are commonly experienced at the recommended dose of 750 mg/d and ∼38% of patients require dose interruption or reduction for GI AEs...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/26937204/neoadjuvant-therapy-for-early-stage-breast-cancer-the-clinical-utility-of-pertuzumab
#15
REVIEW
Jahnavi Gollamudi, Jenny G Parvani, William P Schiemann, Shaveta Vinayak
Approximately 20% of breast cancer patients harbor tumors that overexpress human epidermal growth factor receptor 2 (HER2; also known as ErbB2), a receptor tyrosine kinase that belongs to the epidermal growth factor receptor family of receptor tyrosine kinases. HER2 amplification and hyperactivation drive the growth and survival of breast cancers through the aberrant activation of proto-oncogenic signaling systems, particularly the Ras/MAP kinase and PI3K/AKT pathways. Although HER2-positive (HER2(+)) breast cancer was originally considered to be a highly aggressive form of the disease, the clinical landscape of HER2(+) breast cancers has literally been transformed by the approval of anti-HER2 agents for adjuvant and neoadjuvant settings...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/26893581/egfr-testing-and-clinical-management-of-advanced-nsclc-a-galician-lung-cancer-group-study-ggcp-048-10
#16
Sergio Vázquez, Joaquín Casal, Francisco Javier Afonso Afonso, José Luis Fírvida, Lucía Santomé, Francisco Barón, Martín Lázaro, Carolina Pena, Margarita Amenedo, Ihab Abdulkader, Carmen González-Arenas, Laura Fachal, Ana Vega
PURPOSE: This study aimed to assess the incidence of mutations in the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients in the Galician region of Spain and the clinical management and outcome of patients carrying EGFR mutations. PATIENTS AND METHODS: All newly diagnosed advanced or metastatic NSCLC patients were screened for EGFR mutations in matched tumor samples (tissue or cytology specimens) and serum samples. RESULTS: Of 198 patients screened for EGFR mutations in tumor samples, 184 had evaluable data and, of these, 25 (13...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/26855598/hemoglobin-levels-and-quality-of-life-in-patients-with-symptomatic-chemotherapy-induced-anemia-the-eaqua-study
#17
Jean-Loup Mouysset, Beata Freier, Joan van den Bosch, Charles Briac Levaché, Alain Bols, Hans Werner Tessen, Laura Belton, G Chet Bohac, Jan-Henrik Terwey, Giuseppe Tonini
PURPOSE: To assess hemoglobin (Hb) outcomes and fatigue-related quality-of-life (QoL) (electronic assessment) in patients with solid tumors and symptomatic chemotherapy-induced anemia receiving cytotoxic chemotherapy and darbepoetin alfa (DA) or another erythropoiesis-stimulating agent according to European indication. METHODS: eAQUA was a Phase IV prospective observational study. The primary outcome (assessed in the primary analysis set [PAS]: patients receiving one or more DA dose who had baseline and week 9 assessments for Hb and QoL) was the proportion of patients receiving DA having both Hb increases ≥1 g/dL and improved QoL between baseline and week 9...
2016: Cancer Management and Research
https://www.readbyqxmd.com/read/26673410/development-and-validation-of-an-immunohistochemistry-assay-to-assess-glucocorticoid-receptor-expression-for-clinical-trials-of-mifepristone-in-breast-cancer
#18
Gabrielle M Baker, Tiffany Murphy, Thaddeus Block, Dat Nguyen, Frank J Lynch
BACKGROUND: Glucocorticoid receptor (GR) activity has been associated with chemotherapy resistance and poor outcomes in patients with triple negative breast cancer (TNBC). The aim of this study was to develop an immunohistochemistry (IHC) assay to assess GR expression in archival formalin-fixed, paraffin-embedded human invasive breast carcinoma samples. METHODS: An optimized GR assay protocol was developed using rabbit monoclonal antibody to GR clone D8H2. Precision and reproducibility of the GR IHC assay was determined by conducting multiple staining runs of four invasive breast carcinoma samples using replicate serial sections...
2015: Cancer Management and Research
https://www.readbyqxmd.com/read/26648755/clinical-utility-of-rapidarc%C3%A2-radiotherapy-technology
#19
REVIEW
Erminia Infusino
RapidArc™ is a radiation technique that delivers highly conformal dose distributions through the complete rotation (360°) and speed variation of the linear accelerator gantry. This technique, called volumetric modulated arc therapy (VMAT), compared with conventional radiotherapy techniques, can achieve high-target volume coverage and sparing damage to normal tissues. RapidArc delivers precise dose distribution and conformity similar to or greater than intensity-modulated radiation therapy in a short time, generally a few minutes, to which image-guided radiation therapy is added...
2015: Cancer Management and Research
https://www.readbyqxmd.com/read/26640390/durable-response-using-regorafenib-in-an-elderly-patient-with-metastatic-colorectal-cancer-case-report
#20
Ronald Tang, Tatiana Kain, June Herman, Tara Seery
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer. Since this time, however, few case reports outlining real-world usage have been published in the literature. Here, we detail the clinical history of an elderly woman with KRAS wild-type colon cancer who received regorafenib after prior treatment with other agents. We show that by employing dose modification strategies to address adverse events, this patient was able to remain on therapy for 11 months and achieve stable disease...
2015: Cancer Management and Research
journal
journal
42502
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"